Published in Int J Antimicrob Agents on August 07, 2006
The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis (2008) 1.27
Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. J Antimicrob Chemother (2011) 0.85
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 10.37
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics (2004) 4.74
The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis (2011) 4.71
Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J (2004) 4.58
Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis (2007) 3.62
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med (2007) 3.51
Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis (2011) 3.16
Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med (2013) 2.64
Bacterial meningitis in children. Lancet (2003) 2.42
Clinical chorioamnionitis, elevated cytokines, and brain injury in term infants. Pediatrics (2002) 2.39
Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2012) 2.22
Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol (2011) 2.17
Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J (2007) 2.15
Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis (2004) 2.08
Glycerol and bacterial meningitis. Clin Infect Dis (2007) 2.06
Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis (2004) 1.83
Flaws in design and conduct of clinical trials in acute otitis media. Pediatr Infect Dis J (2002) 1.82
Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One (2009) 1.79
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J (2003) 1.75
MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci U S A (2008) 1.74
Human adenovirus infection in Kawasaki disease: a confounding bystander? Clin Infect Dis (2012) 1.69
The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J (2007) 1.67
Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr (2008) 1.63
Viral coinfections in children with invasive pneumococcal disease. Pediatr Infect Dis J (2010) 1.62
Pneumonia and septicemia caused by Burkholderia thailandensis in the United States. J Clin Microbiol (2006) 1.61
Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics (2010) 1.55
Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med (2013) 1.53
Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis (2005) 1.46
Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol (2012) 1.36
Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother (2005) 1.33
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother (2005) 1.32
Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci (2005) 1.28
Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PLoS One (2012) 1.28
Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice. Am J Respir Cell Mol Biol (2004) 1.27
Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease. Infect Immun (2002) 1.26
Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin Infect Dis (2001) 1.25
Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol (2011) 1.22
Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother (2004) 1.21
Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J (2007) 1.20
Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr (2002) 1.20
Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop (2008) 1.18
Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. Virol J (2005) 1.18
Bacterial meningitis in children. Pediatr Clin North Am (2005) 1.16
Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J (2010) 1.16
Decreased innate immune cytokine responses correlate with disease severity in children with respiratory syncytial virus and human rhinovirus bronchiolitis. Pediatr Infect Dis J (2012) 1.15
Differential recruitment of dendritic cells and monocytes to respiratory mucosal sites in children with influenza virus or respiratory syncytial virus infection. J Infect Dis (2008) 1.13
A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis (2002) 1.13
Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood (2008) 1.12
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J (2004) 1.11
Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains. Am J Respir Crit Care Med (2010) 1.10
Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr (2008) 1.09
Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect (2005) 1.09
Concomitant respiratory viral infections in children with Kawasaki disease. Pediatr Infect Dis J (2010) 1.08
Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother (2003) 1.07
Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology. Pflugers Arch (2009) 1.07
Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther (2013) 1.06
Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community-acquired pneumonia. J Clin Microbiol (2004) 1.06
Human metapneumovirus: a not so new virus. Pediatr Infect Dis J (2004) 1.06
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J (2007) 1.05
Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother (2004) 1.05
Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J (2010) 1.04
Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model. J Infect Dis (2008) 1.04